Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVV-01 +/- ICIs in advanced solid tumors
NCT04787003Phase 1Unknown
- Sponsor
- North China Petroleum Bureau General Hospital
- Start
- Feb 2021
- Primary completion
- Oct 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OVV-01 in solid tumor (advanced stage), sponsored by North China Petroleum Bureau General Hospital. Primary endpoints: Maximum Tolerated Dose at 6 months and Number of participants with treatment-related adverse events at 8 months. Status: unknown.
02
Drugs
OVV-01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04787003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787003.